Our goal is to create broader awareness of medical cannabis treatments and the opportunity for doctors to improve the lives of millions of people who currently don't have access to these therapies
As featured on
25 September 2020
Half a million Australians could soon have access to medicinal cannabis
Chronically ill Australians desperately trying to access medicinal cannabis could soon be given a helping hand. Melbourne-based medicinal cannabis company Montu has created a nationwide network of doctors who support the use of cannabidiol (CBD) as a treatment and can help more than half a million patients access the drug for a range of medical conditions, regardless of their location.
1 August 2020
Jupiter Health Clinics and Montu Announce Australia’s Largest Medical Cannabis Partnership for WA
In the largest partnership of its kind in Australia, Montu will work with Jupiter’s WA-based GPs to educate and guide them on how Medical Cannabis can be prescribed to treat more than 30 conditions, such as chronic pain, anxiety and insomnia. WA’s Jupiter Health operates the state’s largest clinic network with more than 300 doctors across 30 clinics.
14 April 2020
Montu’s virtual roundtables educate Australian doctors about medical cannabis during COVID-19
Montu has launched its virtual roundtable series ‘Cannabis Prescriber Discussions’ (CPD) to effectively educate Australian doctors about Medical Cannabis and maintain the conversation during the ongoing COVID-19 restrictions. The CPD series is led by leading prescriber in Montu’s network and provide doctors with the required information and confidence to apply Medical Cannabis to their network of patients..
03 March 2020
Montu launches online platform ‘Circuit’ for doctors to efficiently manage their medical cannabis patients
Australian doctors can now prescribe Medical Cannabis faster and more efficiently to their patients with Montu’s new online platform ‘Circuit’. The recently launched platform provides a streamlined process for Medical Cannabis prescribers and their patients to manage and monitor their prescriptions. It makes the overall prescription process simpler and faster for doctors, patients, and dispensing pharmacies.
10 February 2020
Australia expects cannabis prescriptions will more than double
Australia has seen incredible growth in the number of patients approved for medical cannabis treatment. Unlike some other countries, Australia does not impose restrictions on the conditions or symptoms eligible for medical cannabis treatment. Chronic pain is by far the most common condition authorized for treatment by a medical cannabis product. Other leading conditions approved for treatment include cancer, neuropathic pain, anxiety, and seizure management.
29 January 2020
Department of Health releases 2019 medicinal cannabis numbers
The DoH has published new information, showing that 1,465 doctors have prescribed medical cannabis by the end of 2019. This shows how important the online SAS-B portal, implemented in 2018, has been to meaningfully improve patient access. The DoH has also provided an updated state breakdown for SAS-B approvals, showing that QLD is leading the way with over 10,000 SAS-B approvals in 2019.
29 November 2019
Aleafia Health completes medical cannabis shipment to Montu Group in Australia
The launch of our medical cannabis brand Circle in Australia is strengthened by Aleafia Health’s proven product expertise derived from their proprietary set of over 10 million patient-related data points. This relationship marks an important milestone in supporting our growing network of doctors to access high quality cannabis products.
28 November 2019
Montu Group launches medical cannabis brand Circle into Australian market
Montu Group, a leading medical cannabis company with presence in Europe and Asia-Pacific, is pleased to announce that it has successfully launched its premium medical cannabis brand Circle in the Australian market.
12 November 2019
WA cuts red tape to help patients access medicinal cannabis
The McGowan Labor Government has made it easier for patients to access medicinal cannabis by allowing GP's to prescribe the medication without the need for referral to a specialist. The change brings Western Australia closer into line with other Australian jurisdictions including New South Wales, Queensland and Victoria.
30 September 2019
New South Wales improves access to medicinal cannabis
Following Queensland, the Poisons and Therapeutic Goods Amendment (Cannabis Medicines) Regulation 2019 removes the need for state-level approval, commencing on 30 September 2019. This change will make it easier for patients and doctors to access medicinal cannabis.
03 April 2019
Queensland streamlines medicinal cannabis access
Minister for Health and Ambulance Services Steven Miles said the government had repealed the Public Health (Medicinal Cannabis) Act 2016 to introduce new legislation that makes it easier for patients and doctors to access medicinal cannabis. The law change will significantly streamline the prescription process by removing state-level approval and will ensure patients have access to the treatment they need sooner.
30 July 2018
TGA launches new online system for medicinal cannabis applications
On Monday 30 July 2018, an online system was introduced to enable the electronic submission of Special Access Scheme (SAS) applications and notifications to the Therapeutic Goods Administration (TGA). On 1 December 2018, this system was updated to allow the submission of Authorised Prescriber (AP) applications to the TGA. Use of this online system will reduce administrative burden on health practitioners and provide users with additional system benefits to manage their SAS applications and notifications.
30 October 2016
Medicinal cannabis is now legal in Australia
The Australian parliament passed new national laws today paving the way for the use of medicinal cannabis by people with painful and chronic illness. The legislation was passed by Parliament on 29 February 2016 and will come into effect on 30 October 2016.
Get in touch
We are engaging daily with the medical community, patients, government and other stakeholders in the Australian medical cannabis industry. Contact us if you are looking for first-hand insights into this emerging industry.